A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma
A Phase 2 Open-label, Two-cohort Study to Evaluate Patient Preference for nivolumab + relatlimab Fixed-dose Combination Subcutaneous versus nivolumab + relatlimab Fixed-dose Combination Intravenous and nivolumab Subcutaneous versus nivolumab Intravenous in Participants with Melanoma
Patologie
Stato
Aperto - reclutamento in corso
Codice studio
CA224-1044
Codice EudraCT
2023-504515-33-00
Sponsor/Promotore
Bristol-Myers Squibb
Tipologia
Sperimentale
Fase
II
Unità Operativa
Principal Investigator